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Nanomedicine is an emerging field for developing long-
term sustained and effective therapies for various diseases. 
Due to their diminutive size and unique physical and chemical 
properties, nanoparticles can readily enter the target cells and 
deliver therapeutic payloads in the form of DNA, proteins, or 
drugs. Many recent studies have reported the gene transfer 
ability of numerous metallic and nonmetallic nanoparticles 
in a variety of cells [1-4]. The potential of nanoparticles 
such as gold, albumin, 1,2-dioleoyl-3-trimethylammonium-
propane, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 
and poly(lactic-co-glycolic acid) for developing nonviral 
corneal gene therapy approaches has been recently reported 
[5-7]. Polyethylenimine (PEI) is a polycation that has shown 
high gene transfer efficiency in many cell types [8-11]; yet 
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Purpose: To explore (i) the potential of polyethylenimine (PEI)-DNA nanoparticles as a vector for delivering genes into 
human corneal fibroblasts, and (ii) whether the nanoparticle-mediated soluble extracellular domain of the transforming 
growth factor–β type II receptor (sTGFβRII) gene therapy could be used to reduce myofibroblasts and fibrosis in the 
cornea using an in vitro model.
Methods: PEI-DNA nanoparticles were prepared at a nitrogen-to-phosphate ratio of 30 by mixing linear PEI and a 
plasmid encoding sTGFβRII conjugated to the fragment crystallizable (Fc) portion of human immunoglobulin. The 
PEI-DNA polyplex formation was confirmed through gel retardation assay. Human corneal fibroblasts (HCFs) were 
generated from donor corneas; myofibroblasts and fibrosis were induced with TGFβ1 (1 ng/ml) stimulation employing 
serum-free conditions. The sTGFβRII conjugated to the Fc portion of human immunoglobulin gene was introduced into 
HCF using either PEI-DNA nanoparticles or Lipofectamine. Suitable negative and positive controls to compare selected 
nanoparticle and therapeutic gene efficiency were included. Delivered gene copies and mRNA (mRNA) expression were 
quantified with real-time quantitative PCR (qPCR) and protein with enzyme-linked immunosorbent assay (ELISA). The 
changes in fibrosis parameters were quantified by measuring fibrosis marker α-smooth muscle actin (SMA) mRNA and 
protein levels with qPCR, immunostaining, and immunoblotting. Cytotoxicity was determined using cellular viability, 
proliferation, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay.
Results: PEI readily bound to plasmids to form nanoparticular polyplexes and exhibited much greater transfection ef-
ficiency (p<0.01) than the commercial reagent Lipofectamine. The PEI-DNA-treated cultures showed 4.5×104 plasmid 
copies/µg DNA in real-time qPCR and 7,030±87 pg/ml sTGFβRII protein in ELISA analyses, whereas Lipofectamine-
transfected cultures demonstrated 1.9×103 gene copies/µg DNA and 1,640±100 pg/ml sTGFβRII protein during these 
assays. The PEI-mediated sTGFβRII delivery remarkably attenuated TGFβ1-induced transdifferentiation of corneal 
fibroblasts to myofibroblasts in cultures, as indicated by threefold lower levels of SMA mRNA (p<0.01) and significant 
inhibition of SMA protein (up to 96±3%; p<0.001 compared to no-gene-delivered cultures) in immunocytochemical 
staining and immunoblotting. The nanoparticle-mediated delivery of sTGFβRII showed significantly better antifibrotic 
effects than the Lipofectamine under similar experimental conditions. However, the inhibition of myofibroblast in HCF 
cultures by sTGFβRII overexpression by either method was significantly higher than the naked vector transfection. Fur-
thermore, PEI- or Lipofectamine-mediated sTGFβRII delivery into HCF did not alter cellular proliferation or phenotype 
at 12 and 24 h post-treatment. Nanoparticles treated with HCF showed more than 90% cellular viability and very low 
cell death (2–6 TUNEL+ cells), suggesting that the tested doses of PEI-nanoparticles do not induce significant cell death.
Conclusions: This study demonstrated that PEI-DNA nanoparticles are an attractive vector for the development of 
nonviral corneal gene therapy approaches and that the sTGFβRII gene delivery into keratocytes could be used to control 
corneal fibrosis in vivo.
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its potential for corneal gene therapy has not been tested. 
PEI efficiently condenses DNA to form stable functionalized 
nanoparticles [12]. After their cellular uptake, PEI’s proton 
sponge effect facilitates gene expression by causing efficient 
DNA release from endosomes due to proton and chloride 
influx, thus leading to endosome rupture by osmotic swelling 
[13]. Branched and linear PEIs are available; although both 
show efficient gene transfer, linear PEI is less toxic in vivo 
[14,15]. In particular, a 22 kDa linear PEI has been shown to 
have high transfection efficiency both in vitro and in vivo 
[11-15].
Corneal fibrosis is an expected outcome of uncontrolled 
wound healing following injury or infection. Corneal healing 
is an intricate process involving increased cytokine expres-
sion, keratocyte activation, myofibroblast formation, and 
increased extracellular matrix (ECM) deposition [16-19]. 
Uneven ECM deposition and formation of light-scattering 
myofibroblasts are thought to be the underlying causes of 
corneal fibrosis [18,19], with TGFβ as a key cytokine involved 
in the pathophysiology of corneal fibrosis due to its increased 
expression in tear fluid and stroma in injured corneas [20,21]. 
In vitro TGFβ treatment of corneal keratocytes or fibroblasts 
induces myofibroblast formation, stimulates cytoskeletal 
and ECM protein synthesis, and reduces ECM degradation 
by decreasing matrix metalloproteinases, collagenase, and 
stromelysin expression [22-24]. Silencing of hyper-TGFβ 
activity with small molecule inhibitors, genes, antisense 
oligos, or neutralizing antibodies is effective in preventing 
corneal fibrosis in various animal models [25-29].
It has been our longstanding central hypothesis that 
selective sequestering of TGFβ by anti-TGFβ genes is an 
attractive approach to treat corneal fibrosis. We found that 
anti-TGFβ gene therapy delivered with nonpathogenic adeno-
associated viruses effectively reduced corneal fibrosis in vivo 
in a rabbit model [29], but little research has been done to 
identify potent nonviral vehicles such as nanoparticles for 
corneal disease treatment. Gene-based therapy eliminates 
many challenges of conventional therapy, including repeated 
applications and side effects. In the present study, we report 
PEI-DNA nanoparticles as a vector for introducing thera-
peutic genes into corneal cells and the effectiveness of soluble 
extracellular domain of the TGFβ type II receptor to inhibit 
TGFβ-induced formation of myofibroblasts in the cornea 
using an in vitro model.
METHODS
Human corneal fibroblast and myofibroblast cultures: 
Primary corneal fibroblast cultures were generated from 
donor human corneas procured from an eye bank (Heartland 
Eye Bank, Kansas City, MO) as reported previously [28]. 
Briefly, corneal tissues were washed with sterile cell culture 
medium, and the epithelium and endothelium were removed 
by gentle scraping with a scalpel blade (#15). The corneal 
stroma was cut into small pieces, placed on culture dish 
and incubated in a humidified 5% CO2 incubator at 37 °C 
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum for 2 weeks or longer. 
The primary human corneal fibroblasts (HCFs) harvested 
from these corneal buttons were seeded in six-well plates 
in DMEM supplemented with 10% fetal bovine serum 
and allowed to reach 60%–70% confluence. To generate 
myofibroblast cultures, HCFs were seeded using DMEM 
containing 10% serum, after 8–12 h switched to serum-free 
medium containing TGFβ1 (1 ng/ml), and incubated for 4–7 
days. The cultures were fed with fresh serum-free TGFβ1 
containing medium every 24 h.
Vector construct, polyethylenimine-DNA nanoparticles, 
and transfection: The 477-nucleotide sequence encoding 
for extracellular domain of human TGFβRII (sTGFβRII) 
conjugated to a 681 intronless nucleotide sequence encoding 
for a fragment crystallizable (Fc) portion of human immuno-
globulin (IgG) was cloned into pcDNA3.1 mammalian gene 
expression vector, as reported previously [30]. Restriction 
mapping and DNA sequencing were used to confirm the 
nucleotide sequence of the construct.
The PEI-DNA nanoparticle transfection mixture 
(nitrogen-to-phosphate ratio 30) was prepared by adding 
appropriate amounts of 150 mM linear 22 kDa PEI [31] in 
100 μl of water dropwise with constant stirring to 2 μg of 
plasmid (pcDNA3.1-sTGFβRII-Fc) solubilized in 100 μl of 
PBS containing 10% glucose (w/v). The reaction mixture was 
then incubated at 37 °C for 30 min. The PEI plasmid DNA 
complexation was confirmed using a gel retardation assay by 
loading onto a 1% agarose gel containing ethidium bromide 
and subjecting to electrophoresis with a Tris-acetate running 
buffer. The Lipofectamine transfection solution was prepared 
by incubating 5 µl Lipofectamine 2000 (Invitrogen, Carlsbad, 
CA) in 250 µl of serum-free DMEM with 2 µg of DNA in 
250 µl of serum-free DMEM for 30 min at room temperature.
Transfections of HCF were performed by incubating HCF 
cultures with 200 μl of PEI-DNA solution in 2 ml DMEM 
medium containing 10% serum for 30 min or Lipofectamine-
DNA mixture in 2 ml DMEM serum-free medium for 6 h (as 
recommended by the vendor), since no DNA delivery was 
detected after 30 min incubation. After transfection-solution 
incubation, cultures were washed with PBS and allowed to 
grow in serum-free DMEM medium containing TGFβ1 (1 
ng/ml) for 4–7 days (80% confluence).
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Immunofluorescence: Cells were fixed with 4% paraformal-
dehyde, and immunofluorescence staining for α–smooth 
muscle actin (αSMA; a marker for myofibroblast) was 
performed. Samples were incubated with 5% BSA for 30 
min at room temperature, followed by mouse monoclonal 
αSMA antibody (1:200 dilution, Dako, Carpinteria, CA) 
for 90 min and Alexa 488 goat anti-mouse IgG secondary 
antibody (1:500 dilution) for 1 h. The cells were washed three 
times in HEPES buffer, mounted in Vectashield containing 
4’-6-diamidino-2-phenylindole (DAPI; Vector Laboratories), 
and viewed and photographed with a Leica fluorescent micro-
scope (Leica DM 4000B) equipped with a digital camera 
(SpotCam RT KE).
Immunoblotting: The treated/untreated HCF cultures were 
lysed in radioimmunoprecipitation assay (RIPA) lysis buffer 
containing a protease inhibitor cocktail (Roche Applied 
Sciences, Indianapolis, IN), followed by centrifugation at 
10,000 g for 10 min. Samples were suspended in NuPAGE 
LDS buffer containing a reducing agent (Invitrogen) and 
heated at 70 °C for 10 min. Protein samples were resolved 
by NuPAGE Novex Bis-Tris mini gels (Invitrogen) and trans-
ferred onto the polyvinylidene difluoride membranes using 
an iBlot apparatus (Invitrogen). The transferred proteins were 
detected by incubating the membrane with primary anti-
bodies: αSMA (Dako) and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH; Santa Cruz Biotechnology, Santa Cruz, 
CA), followed by alkaline phosphatase conjugated anti-mouse 
secondary antibody. After washing three times in 0.05% 
Tween-20 in Tris-buffered saline of pH 8.0 for 5 min each, 
the blot was developed using the nitroblue tetrazolium/5-
bromo-4-chloro-3-indolylphosphate method. Three separate 
western blots were performed for each experiment. The 
digital quantification of western blots was performed using 
Image J software. The quantification intensity was normal-
ized against GAPDH bands.
RNA extraction, cDNA synthesis, and quantitative real-time 
PCR: Total RNA from cells was extracted with an RNeasy 
kit (Qiagen, Valencia, CA) and reverse transcribed to cDNA 
following vendor’s instructions (Promega, Madison, WI). 
Real-time PCR was then performed using Step One Plus 
real-time PCR system (Applied Biosystems, Carlsbad, CA). 
A 20-µl reaction mixture containing 2 µl of cDNA, 2 µl of 
forward primer (200 nM), 2 µl of reverse primer (200 nM), 
and 10 µl of 2X SYBR green super mix (Bio-Rad Laborato-
ries) was run at a universal cycle (95 °C for 10 min, 40 cycles 
at 95 °C for 15 s, and 60 °C for 60 s) in accordance with the 
manufacturer’s instructions. For alpha smooth muscle actin 
(αSMA), the forward primer sequence TGG GTG ACG AAG 
CAC AGA GC and the reverse primer sequence CTT CAG 
GGG CAA CAC GAA GC were used. β-actin forward primer 
CGG CTA CAG CTT CAC CAC CA and reverse primer CGG 
GCA GCT CGT AGC TCT TC were used as housekeeping 
genes.
Quantification of gene copy number: The copies of delivered 
plasmid were determined using real time PCR. DNA was 
isolated from corneal fibroblasts using a DNeasy kit (Qiagen). 
The standard plot was prepared using a 10 fold serial dilution 
of 1011-106 copies of sTGFβRII pCDNA3.1 plasmid. Forward 
primer ACG GTG CAG TCA AGT TTC CAC AAC and 
reverse primer ACA CAG ACT TCC TGT GGC TTC TCA 
were used for running the real time PCR with the following 
settings: 95 °C for 10 min, 40 cycles at 95 °C for 15 s, and 
60 °C for 60 s.
Quantification of protein expression due to delivered gene: 
Sandwich ELISA for sTGFβRII was done on the culture 
medium collected from sTGFβRII-transfected HCF. The 
collected medium was concentrated using a centrifugal 
Vacuum Concentrator (Labconco), and ELISA was performed 
following manufacturer’s instructions using a commercially 
available kit (R&D Systems, Minneapolis, MN).
Cytotoxicity of polyethylenimine-DNA nanoparticles: The 
PEI-DNA nanoparticles cytotoxicity to HCF was evaluated 
measuring cellular proliferation with MTT, total cell counts 
with DAPI-staining and apoptotic cell death with TUNEL 
assays following vendors’ instructions. Briefly, for MTT 
assay (Promega), 5000 HCF were seeded in a 96 well plate 
and exposed to PEI-DNA nanoparticles mixture for 30 min, 
and at 2, 6, 12, and 24 h post-transfection cellular prolifera-
tion was quantified by measuring change in color intensity 
using spectrophotometer. To compare total cell counts in 
±nanoparticles treated HCF, DAPI-stained nuclei at 200X 
magnification in six randomly selected, non-overlapping 
areas were counted. To determine cell death, cultures were 
fixed in paraformaldehyde, washed with PBS, subjected to 
TUNEL assay (Millipore), and TUNEL+cells in ±nanopar-
ticles treated cultures at 200X magnification in six randomly 
selected, non-overlapping areas were counted.
Statistical analyses: Results were expressed as a 
mean±standard error. Statistical analysis was performed 
using One way ANOVA and Tuckey’s test. The standard 
curve for the gene copy number and ELISA was subjected to 
regression analysis, and slope, intercept and correlation coef-
ficient were calculated. The value of p<0.05 was considered 
significant.
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RESULTS
Formation of polyethylenimine-plasmid polyplex: The forma-
tion of PEI-DNA polyplex was confirmed by inhibition of 
DNA migration using agarose gel electrophoresis. As detected 
in Figure 1, the PEI completely inhibited electrophoretic 
migration of DNA suggesting complex formation between the 
positively charged PEI and the negatively charged plasmid. 
PEI complexation to plasmid prevents the ethidium bromide 
dye from binding to the DNA resulting in no staining of the 
DNA band in the wells. The control, plasmid DNA alone, 
showed normal electrophoretic migration in gel and ethidium 
bromide staining (Figure 1).
Determination of delivered soluble transforming growth 
factor–β type II receptor gene copies: The sTGFβRII 
gene copies delivered into HCF with nanoparticles or lipo-
fectamine were quantified with real-time PCR and are shown 
in Figure 2. Detection of 4.5×104 sTGFβRII gene copies per 
µg DNA delivered with nanoparticles and 0.2×104 sTGFβRII 
gene copies per µg DNA delivered with lipofectamine into 
HCF demonstrated high transfection efficiency of PEI-DNA 
nanoparticles (Figure 2A).
Quantification of soluble transforming growth factor–β 
type II receptor protein: To ensure that nanoparticle-medi-
ated sTGFβRII-Fc plasmid delivery results in successful 
gene transcription and secretion of sTGFβRII protein, the 
protein levels of secreted sTGFβRII in the culture medium 
of transfected HCF were quantified using ELISA assay 
(Figure 2B). The nanoparticle-transfected HCF showed a 
Figure 1. Agarose gel electrophoresis showing DNA migration and 
polyplex formation between PEI and plasmid. Plasmid alone showed 
DNA migration (lane-2) but no DNA migration was detected in 
polyplex (lane-3) or PEI alone (lane-1) on the gel. L: denotes 1 kb 
plus DNA ladder loading.
Figure 2. Real-time PCR. A: and ELISA B: showing quantification of delivered transgene gene copy number and protein levels in human 
corneal fibroblasts. The nanoparticle-transfected cultures showed high 4.5×104 plasmid copies per µg DNA. This was statistically more than 
the lipofectamine or un-transfected cultures (ψ; p<0.001). Also, nanoparticle transfected cultures showed significantly high 7,030±87 pg/ml 
of sTGFβRII levels in ELISA assay of culture medium compared to un-transfected (ψ; p<0.001) and lipofectamine-transfected (ϕ; p<0.01) 
cultures. Lipofectamine-transfected HCF showed 1640±100 pg/ml of sTGFβRII (*, p<0.001 compared to un-transfected). The un-transfected 
HCF showed undetectable protein levels of sTGFβRII.
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significantly high 7,030±87 pg/ml protein levels of sTGFβRII 
in the culture medium obtained from HCF transfected with 
PEI-sTGFβRII-Fc plasmid (p<0.001 compared to untrans-
fected; p<0.01 compared to lipofectamine-transfected). 
Contrary to this, lipofectamine-transfected HCF showed 
1,640±100 pg/ml of sTGFβRII in the culture medium (p<0.001 
compared to untransfected). The naked vector transfected 
controls showed no detectable levels of sTGFβRII protein in 
ELISA. These results confirm successful transgene expres-
sion in the HCF transfected with PEI-DNA nanoparticles and 
suggest that tested nanoparticles are a more efficacious vector 
for HCF than the lipofectamine.
Effect of soluble transforming growth factor–β type II 
receptor gene delivery on myofibroblasts and fibrosis: The 
transformation of corneal fibroblasts to myofibroblasts has 
been identified as the primary event in corneal fibrosis devel-
opment. Myofibroblasts are contractile, metabolically active 
and opaque cells containing intracellular microfilament 
bundles of F-actin and αSMA. To test the antifibrotic effect 
of nanoparticles or lipofectamine delivered sTGFβRII-Fc, the 
mRNA and protein levels of αSMA were quantified using 
real-time PCR (Figure 3A), immunoblotting (Figure 3B) and 
immunostaining (Figure 4). As seen in Figure 3A, TGFβ1 
treatment to corneal fibroblasts caused a 5.0±1.4 (p<0.01) fold 
increase in the mRNA expression of αSMA, and a significant 
decrease in αSMA mRNA levels were detected in cultures 
that were transfected with sTGFβRII-Fc with nanoparticles 
(0.36±0.08 fold; p<0.01) or lipofectamine (3.3±0.5 fold; 
p<0.05) compared to TGFβ1 alone treatment. Indeed, the 
inhibitory effects were more pronounced in cultures in which 
sTGFβRII was introduced via nanoparticles instead of lipo-
fectamine (Figure 3A).
Figure 3B shows the results of αSMA immunoblotting 
performed with protein lysates prepared from HCF cultures 
transfected with nanoparticle or lipofectamine and grown 
in ±of TGFβ1. Samples with no-TGFβ1 treatment showed a 
faint αSMA band, TGFβ1 treatment induced myofibroblast 
production resulting in a prominent αSMA band, whereas 
sTGFβRII-Fc-transfection arrested myofibroblast forma-
tion as indicated by the detection of a weak αSMA bands 
in nanoparticle or lipofectamine transfected samples (Figure 
3B). The digital quantification of three independent western 
Figure 3. Quantification of αSMA mRNA. A: and protein B: levels in ±TGFβ1 treated HCF cultures showing anti-fibrotic response of 
sTGFβRII-Fc gene transfer. A: Real-time PCR showed that TGFβ1 treatment caused 5±1.4 fold increase in αSMA mRNA (#; p<0.01 than 
TGFβ1 untreated) and nanoparticle-mediated sTGFβRII-Fc transfection significantly lowered αSMA mRNA (0.36±0.08 fold, ψ; p<0.01 
compared to TGFβ1-treated and ϕ; p<0.05 compared to lipofectamine-transfected). B: In western blotting an expected significant increase 
in αSMA levels were detected in TGFβ1-treated HCF over the TGFβ1-untreated HCF (#; p<0.001). Nanoparticles-mediated sTGFβRII-Fc 
gene transfer into HCF demonstrated a significant 96±3% decrease in αSMA levels (ψ; p<0.001 compared to TGFβ1-treated and ϕ; p<0.01 
compared to lipofectamine-transfected). Lipofectamine-delivered sTGFβRII-Fc HCF used for comparison showed less than 60% decrease 
in αSMA expression.
Molecular Vision 2012; 18:2598-2607 <http://www.molvis.org/molvis/v18/a269> © 2012 Molecular Vision 
2603
blotting experiments (Figure 3C) found that PEI-mediated 
sTGFβRII-Fc transfection caused a statistically significant 
decrease in αSMA (96±3%; p<0.001 compared to TGFβ1-
treated), which was 30% (p<0.01) more than the lipofectamine 
transfection. Lipofectamine-mediated sTGFβRII-Fc transfec-
tion to HCF showed 68.0±1.4% αSMA reduction (p<0.001 
compared to TGFβ1-treated). This data suggests that 
sTGFβRII gene delivery reduces corneal fibrosis and that 
the nanoparticle-mediated gene transfer was more efficient 
compared to lipofectamine’s.
The anti-fibrotic effects of sTGFβRII-Fc gene transfer 
were further investigated by αSMA immunocytochemistry 
(Figure 4). As expected HCF cultured in the absence of 
TGFβ1 under serum-free conditions showed minimal αSMA 
expression (Figure 4A) whereas TGFβ1 (1 ng/ml) treatment 
caused a robust myofibroblast formation as indicated by an 
intense αSMA immunostaining in cultures (Figure 4B). The 
lipofectamine-mediated sTGFβRII-Fc transfection showed 
63±4% (Figure 4C) and nanoparticle-mediated sTGFβRII 
gene transfer inhibited 94±5% myofibroblast formation 
(Figure 4D). The quantification of αSMA carried-out by 
counting αSMA+ and DAPI-stained nuclei in 10 randomly 
selected 200X magnification fields found that sTGFβRII gene 
transfer accomplished with nanoparticles was significantly 
more efficacious than the TGFβ1 treated un-transfected 
(Figure 4B; 94±5%, p<0.001) or lipofectamine-transfected 
cells (Figure 4C; 43±4%; p<0.01).
Effect of nanoparticles on cellular proliferation and cell death: 
Figure 5 shows the effects of nanoparticles (PEI-sTGFβRII-Fc 
plasmid) on cellular proliferation measured with MTT assay 
(Figure 5A) and total cell loss determined with DAPI-staining 
(Figure 5B) at various time points. As seen in Figure 5A, 
tested nanoparticles showed 22–24±3% (p<0.05) decrease in 
cellular proliferation up to 6 h. Nonetheless, this decrease 
in cellular proliferation was transient as no differences in 
cellular proliferation were detected between the nanoparticle-
transfected and un-transfected HCF at 24 h post-treatment 
(Figure 5A). An expected 7%–9% loss of cells was detected in 
nanoparticle-transfected cultures compared to un-transfected 
cultures at 12- and 24 h post-treatment (Figure 5B).
Figure 6 shows results of TUNEL assay that primarily 
detects apoptosis and necrosis to a lesser extent. Detection of 
2–5 TUNEL+ cells in 200X magnification field in nanopar-
ticle-transfected (Figure 6A) and un-transfected (Figure 6B) 
cultures 24 h post-treatment suggests that PEI-sTGFβRII 
nanoparticles do not induce cell death.
Figure 4. Immunocytochemistry 
showing the effects of nanopar-
ticles-mediated sTGFβRII gene 
transfer on αSMA and myofibro-
blast inhibition. No αSMA+ cells 
were detected in un-transfected 
HCF grown in the absence of 
TGFβ1 A: and >80% αSMA+ cells 
were detected in cultures grown in 
presence of TGFβ1 B: The nanopar-
ticles mediated sTGFβRII-Fc gene 
delivery into HCF decreased 
αSMA+ cells D: >90% compared 
to TGFβ1-treated (p<0.001) and 
>68% than lipofectamine-delivered 
sTGFβRII C: p<0.01. Scale bar 
denotes 50 μm.
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DISCUSSION
Poor transfection efficiency of non-viral vectors for corneal 
cells is a limiting factor in the development of non-viral 
gene therapy for corneal diseases. Nanoparticles can serve 
as an efficient gene therapy vectors [1-6]. In this study, we 
report that PEI-DNA nanoparticles are efficient vector for 
delivering genes into corneal cells without compromising 
cellular proliferation, phenotype or viability, and that 
nanoparticle-assisted delivery of genetic material encoding 
for therapeutic gene, sTGFβRII-Fc chimeric protein secreted 
as a dimer, remarkably attenuates myofibroblast formation 
using an established in vitro corneal fibrosis model. Further, 
results of our study suggest that the tested nanoparticles offer 
greater gene transfer and therapeutic response compared to 
the commercial reagent, lipofectamine, in vitro.
A primary event in corneal fibrosis development is 
the transdifferentiation of quiescent corneal keratocytes to 
fibroblasts and myofibroblasts accompanied by increased 
deposition of collagen and matrix proteins [18,19]. After 
wound repair, myofibroblasts presumably disappear through 
Figure 5. Quantification of MTT assay. A: and DAPI-stained nuclei B: data showing the effects of nanoparticles on cellular proliferation 
and survival/loss. A: Cell proliferation was quantified by measuring reduction of tetrazolium to formazan by live cells in MTT assay. 
The nanoparticles treatment to HCF did not cause overall impact HCF proliferation except showing early transient decrease in cellular 
proliferation at 2- and 6-h time points (22–24±3%; p<0.05) compared to untreated control. B: The DAPI-stained nuclear counting showed 
that nanoparticles are non-cytotoxic to HCF at 12 and 24 h.
Figure 6. TUNEL assay performed 24 h after the PEI-DNA nanoparticles treatment showed that tested nanoparticles do not cause HCF 
death. No significant differences in TUNEL+ cells (Red) were seen in the untreated A: and nanoparticle-untreated B: HCF at 24 h. Nuclei 
are stained blue with DAPI. Scale bar denotes 100 μm.
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apoptosis although the actual molecular mechanism of their 
disappearance is still unclear. Myofibroblast formation and 
haze development in cornea is largely mediated by hyper-
TGFβ activity following corneal insult [20,21]. Additionally, 
TGFβ also stimulates the de novo synthesis of the extracel-
lular matrix proteins, and thus further contributes to the 
corneal fibrosis and opacity development [23,24]. It is our 
working hypothesis that blocking of TGFβ or its signaling 
is a promising strategy to attenuate myofibroblast and scar 
formation in the cornea. We and others researchers have 
previously reported promising results to reduce corneal 
fibrosis by inhibiting TGFβ with antisense oligonucleotides, 
antibodies or genes like decorin, Smad7 etc [25-29]. However, 
a novel strategy to block TGFβ signaling in a TGFβ-specific 
manner is needed. Thus, we generated a vector expressing 
an ectodomain of the soluble type II TGFβ receptor fused 
to the Fc portion of human IgG and tested its potential for 
gene therapy using an in vitro corneal fibrosis model. The 
sTGFβRII blocks TGFβ signaling most probably by adsorbing 
TGFβ, although there is a possibility that it may also work 
as a dominant-negative receptor. Indeed, detection of high 
sTGFβRII protein in culture medium and a remarkable 
decrease in myofibroblasts not only supported our hypoth-
esis but also demonstrated the promise of this approach for 
treating corneal scarring. We further postulate that high 
myofibroblast inhibition by sTGFβRII-Fc is due to the 
therapeutic chimeric protein produced as a dimer that binds 
and neutralizes TGFβ several fold more than its monomer 
form [32]. Preclinical animal studies have shown significant 
resolution of fibrosis in lung and kidney after sTGFβRII-Fc 
gene therapy delivered via adenovirus or non-viral vector 
[32-34]. Contrary to these findings, few studies did not find 
sTGFβRII-Fc gene transfer effective [35]. These conflicting 
reports suggest that anti-fibrotic effects of sTGFβRII-Fc are 
tissue-specific. We speculate that nanoparticle-mediated 
sTGFβRII-Fc gene therapy in the cornea in vivo will 
effectively reduce corneal opacity and effects will be long 
lasting due to the prolonged half-life of therapeutic chimeric 
sTGFβRII-Fc protein, which has shown extended in vivo half-
life in various tissues [32-34]. However, its half-life in the 
cornea is yet to be determined.
Nanoparticles used in this study were prepared from 
PEI, which may cause cellular toxicity depending on their 
shape, size and molecular weight as branched PEI is reported 
cytotoxic to a variety of cells [8,9]. Conversely, linear PEI 
was found less cytotoxic and showed little damage to cell 
membrane and mitochondrial function or change in cellular 
viability and proliferation in many cell types [11,12,15]. The 
linear PEI-DNA nanoparticles, tested in present study did 
not alter human corneal fibroblasts proliferation, viability or 
induced cellular death. This suggests that PEI-DNA nanopar-
ticles are not cytotoxic to corneal cells and warrants their in 
vivo testing. Another interesting observation is a prolifera-
tion slowdown of human corneal fibroblasts at an early 12 
h period with these nanoparticles. Although, the relevance 
of this observation at this time is unclear, we postulate that 
this would have role in reducing myofibroblasts development 
in the cornea. It is well documented that active proliferation 
of quiescent keratocytes immediately after ocular injury 
plays an important role in corneal wound healing and leads 
to myofibroblasts and haze formation in the cornea [36,37]. 
It remains to be studied whether transient early arrest of 
corneal fibroblast proliferation by selected PEI nanoparticles 
will have any affect on corneal wound healing. Future in 
vivo studies will address this issue. In summary, this study 
demonstrates that PEI-DNA nanoparticles are potent and safe 
vector for introducing therapeutic genes into corneal cells to 
treat disorders, and sTGFβRII-Fc gene therapy delivered with 
these nanoparticles could be an effective approach to control 
corneal healing and treat corneal scarring in vivo.
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